桑杏止咳方治疗干燥低海拔地区燥邪伤肺证咳嗽变异性哮喘的临床效果

Clinical effect of Sangxing Zhike Prescription in treating cough variant asthma with dryness pathogen impairing lung syndrome in dry and low altitude area

目的探讨桑杏止咳方治疗干燥低海拔地区燥邪伤肺证咳嗽变异性哮喘(CVA)的临床效果。方法选取2022年1月至2023年9月就诊于新疆吐鲁番市高昌区人民医院呼吸科240例CVA患者,按照随机数字表法将其分为对照组和观察组,各120例。两组持续治疗2周,比较患者治疗前后临床疗效、莱赛斯特咳嗽生命质量评分(LCQ)、咳嗽视觉模拟评分(VAS)、肺功能、中性粒细胞、嗜酸性粒细胞变化。结果观察组临床疗效优于对照组,差异有统计学意义(P<0.05)。治疗前,两组LCQ和VAS评分比较,差异无统计学意义(P>0.05);治疗后,两组LCQ评分均较治疗前升高,且观察组高于对照组,两组VAS评分较治疗前降低,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗前,两组肺功能比较,差异无统计学意义(P>0.05);治疗后,观察组用力肺活量(FVC)高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组第一秒用力呼气量(FEV_(1))、FEV_(1)/FVC肺功能高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗前,两组中性粒细胞计数、淋巴细胞计数、中性粒细胞/淋巴细胞比值及嗜酸性粒细胞计数比较,差异无统计学意义(P>0.05);治疗后,两组中性粒细胞计数、中性粒细胞/淋巴细胞比值低于治疗前,差异有统计学意义(P<0.05)。治疗后,两组中性粒细胞计数、中性粒细胞/淋巴细胞比值比较,差异无统计学意义(P>0.05)。治疗前,两组淋巴细胞计数、嗜酸性粒细胞计数比较,差异无统计学意义(P>0.05)。治疗后,两组淋巴细胞计数、嗜酸性粒细胞计数与治疗前比较,差异无统计学意义(P>0.05)。治疗后,观察组淋巴细胞计数、嗜酸性粒细胞计数比较高于对照组,差异有统计学意义(P<0.05)。结论桑杏止咳方可降低血清中炎症水平,明显提高CVA患者疗效。

Objective To investigate the clinical effect of Sangxing Zhike Prescription in treating cough variant asthma(CVA)with dryness pathogen impairing lung syndrome in dry and low altitude area.Methods A total of 240 patients with CVA admitted to Department of Respiratory,Gaochang District People’s Hospital in Turpan City,Xinjiang Uygur Autonomous Region from January 2022 to September 2023 were selected and they were divided into control group and observation group according to random number table method,with 120 cases in each group.The two groups were treated continuously for two weeks,and the clinical efficacy,Leicester cough quality of life score(LCQ),visual analogue scale(VAS),pulmonary function,neutrophil,and eosinophilic changes were compared before and after treatment.Results The clinical effect of the observation group was better than that of the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in LCQ and VAS scores between the two groups(P>0.05).After treatment,LCQ score in both groups was higher than before treatment,and that in the observation group was higher than that in the control group,and the VAS score in both groups was lower than before treatment,and that in the observation group was lower than that in the control group,and the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in lung function between the two groups(P>0.05).After treatment,the forced vital capacity(FVC)in observation group was higher than before treatment,and that in observation group was higher than that in control group,and the differences were statistically significant(P<0.05);the forced expiratory volume in first second(FEV_(1)),and FEV_(1)/FVC lung function in both groups were higher than before treatment,and those in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in neutrophil count,lymphocyte count,neutrophil/lymphocyte ratio,and eosinophilic count between the two groups(P>0.05).After treatment,neutrophil count and neutrophil/lymphocyte ratio in two groups were lower than before treatment,and the differences were statistically significant(P<0.05).After treatment,there was no significant difference in neutrophil count and neutrophil/lymphocyte ratio between the two groups(P>0.05).Before treatment,there was no significant difference in lymphocyte count and eosinophil count between the two groups(P>0.05).After treatment,there was no significant difference in lymphocyte count and eosinophil count between the two groups compared with before treatment(P>0.05).After treatment,the lymphocyte count and eosinophil count in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Sangxing Zhike Prescription can reduce the level of serum inflammation and improve the curative effect of CVA patients.